---
title: "BOJI CRO obtained an invention patent for the \"Method for Determining Gallic Acid in Berberine.\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258037474.md"
description: "BOJI CRO recently obtained an invention patent issued by the National Intellectual Property Administration, with the patent name \"A Method for Determining Gallic Acid in Berberine,\" certificate number 8272934, patent number ZL202510318197.1. This method has good separation effects in the field of drug component detection, with a short detection time and high resolution. Although it has little impact on the company's operating performance, it helps with technological innovation and enhances core competitiveness"
datetime: "2025-09-19T07:59:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258037474.md)
  - [en](https://longbridge.com/en/news/258037474.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258037474.md)
---

# BOJI CRO obtained an invention patent for the "Method for Determining Gallic Acid in Berberine."

Recently, BOJI CRO received an invention patent certificate issued by the National Intellectual Property Administration. The patent is titled "A Method for Determining Gallic Acid in Tannic Acid and Berberine," with certificate number 8272934 and patent number ZL202510318197.1. The application date is March 18, 2025, and the authorization announcement date is September 19, 2025. This method pertains to the field of drug component detection, achieving good separation of tannic acid, berberine, and gallic acid, with a short detection time and high separation degree. Although this patent does not have a significant impact on the company's operating performance, it is beneficial for the company's technological innovation, improving the intellectual property protection system, and enhancing core competitiveness

### Related Stocks

- [300404.CN](https://longbridge.com/en/quote/300404.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [16:51 ETSun Home Luminar Named Best Overall Outdoor Sauna of 2026 in homesauna.com Buyer's Guide](https://longbridge.com/en/news/286818113.md)